Comparative Pharmacology
Head-to-head clinical analysis: NESINA versus SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESINA versus SITAGLIPTIN PHOSPHATE.
NESINA vs SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing their levels and prolonging their action. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner.
25 mg orally once daily.
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Terminal elimination half-life: 12.4 hours (range 8–14 hours). Clinically, supports once-daily dosing with gradual onset of DPP-4 inhibition.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Renal excretion: ~87% (as unchanged drug in urine); biliary/fecal: ~13% (as metabolites and unchanged drug).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor